Abbott's first-quarter sales reached $10.5 billion, a 35.3% increase, driven by strong performance across all four major business segments. The company is particularly pleased with the momentum of recently launched products and forecasts over 35% EPS growth for the year.
Worldwide sales increased by 35.3% on a reported basis and 32.9% on an organic basis.
Diagnostics sales surged by 119.8%, fueled by COVID-19 testing demand.
Medical Devices sales grew by 13.1%, driven by recovery from the COVID-19 pandemic.
Company forecasts more than 35 percent EPS growth for the year.
Abbott projects 2021 diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of at least $3.74. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $5.00 for full-year 2021.